Maverick Capital Ltd. Boosts Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Maverick Capital Ltd. increased its stake in NewAmsterdam Pharma by 57.0%, owning 549,469 shares worth approximately $11.25 million.
• NewAmsterdam Pharma reported a loss of $0.15 per share for the last quarter but exceeded expectations, achieving revenues of $19.15 million.
• The company's stock ratings have improved, with multiple analysts issuing "buy" and "hold" ratings, and a consensus price target of $41.55.

Maverick Capital Ltd. increased its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 57.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 549,469 shares of the company's stock after purchasing an additional 199,464 shares during the period. Maverick Capital Ltd. owned approximately 0.50% of NewAmsterdam Pharma worth $11,248,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares during the period. Northern Trust Corp bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $556,000. Barclays PLC increased its holdings in shares of NewAmsterdam Pharma by 120.0% during the fourth quarter. Barclays PLC now owns 16,713 shares of the company's stock worth $429,000 after purchasing an additional 9,117 shares during the period. Arizona State Retirement System bought a new position in shares of NewAmsterdam Pharma during the first quarter worth approximately $215,000. Finally, California State Teachers Retirement System increased its holdings in shares of NewAmsterdam Pharma by 23.5% during the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock worth $499,000 after purchasing an additional 3,694 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

NAMS traded up $0.78 during midday trading on Thursday, reaching $25.66. The company had a trading volume of 613,987 shares, compared to its average volume of 870,468. The business has a 50-day moving average price of $22.67 and a two-hundred day moving average price of $20.47. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $27.29. The stock has a market cap of $2.89 billion, a PE ratio of -15.84 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The business had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. On average, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NAMS. Needham & Company LLC reissued a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price for the company. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They set an "overweight" rating and a $45.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $41.55.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 8,269 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $24.86, for a total value of $205,567.34. Following the transaction, the chief accounting officer owned 15,000 shares in the company, valued at approximately $372,900. The trade was a 35.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper bought 8,584 shares of the company's stock in a transaction dated Monday, June 16th. The shares were purchased at an average price of $19.50 per share, with a total value of $167,388.00. Following the completion of the acquisition, the director owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This trade represents a 0.28% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 12,835 shares of company stock worth $248,134 and sold 256,881 shares worth $5,445,954. Insiders own 20.84% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.